Peringatan Keamanan

Studies to determine the carcinogenic and its effect in fertility have not been performed. It is important to consider that several corticosteroids have been shown to present genotoxic potential but fluocinolone acetonide was shown to not be genotoxic in the Ames test and mouse lymphoma TK assay.F1957

Fluocinolone acetonide

DB00591

small molecule approved investigational vet_approved

Deskripsi

Fluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity.T357 It has been used extensively in dermatological preparations and it has also been investigated thoroughly for its use in implantable corticosteroid devices.T358 This type of device containing fluocinolone acetonide was developed by Taro Pharmaceuticals and approved by FDA in May 2016.L4676

Struktur Molekul 2D

Berat 452.4882
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The reported half-life of fluocinolone acetonide ranges between 1.3-1.7 hours.[A39536]
Volume Distribusi This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal.
Klirens (Clearance) This pharmacokinetic parameter is not relevant as the systemic absorption of fluocinolone acetonide is very minimal and the concentration in urine is lower than the minimum quantitation limit.[T359]

Absorpsi

When administered as an eye implant, fluocinolone acetonide presents a sustained delivery for even 12 months in which there can be observed a sustained release.L4686 The concentration of fluocinolone acetonide are generally higher in the vitreous and retina with a little dispersion to the aqueous humor.T359 There are reports indicating that topical administration of fluocinolone acetonide produces a percutaneous absorption which is determined by the vehicle, integrity of the epidermal barrier and the use of occlusive dressing.F1956 Independently of the route of administration, the systemic absorption of fluocinolone acetonide is below 0.1 ng/ml which indicates that the systemic distribution is very minimal and the effect of fluocinolone is mainly local.A39533

Metabolisme

Following absorption, fluocinolone acetonide metabolism is primarily hepatic.F1956 It is important to mention that the systemically absorbed dose is very minimal.T359

Rute Eliminasi

Fluocinolone acetonide is mainly excreted by the kidneys.F1956 It is important to mention that the systemically absorbed dose is very minimal.T359

Interaksi Obat

1524 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Fluocinolone acetonide.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluocinolone acetonide.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluocinolone acetonide.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluocinolone acetonide.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluocinolone acetonide.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluocinolone acetonide.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluocinolone acetonide.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluocinolone acetonide.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluocinolone acetonide.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluocinolone acetonide.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluocinolone acetonide.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluocinolone acetonide.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Fluocinolone acetonide.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluocinolone acetonide.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Fluocinolone acetonide.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluocinolone acetonide.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluocinolone acetonide.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluocinolone acetonide.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Fluocinolone acetonide.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluocinolone acetonide.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinolone acetonide.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluocinolone acetonide.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluocinolone acetonide.
Cladribine Fluocinolone acetonide may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Fluocinolone acetonide.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluocinolone acetonide.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluocinolone acetonide.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluocinolone acetonide.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluocinolone acetonide.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluocinolone acetonide.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluocinolone acetonide.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluocinolone acetonide.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluocinolone acetonide.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluocinolone acetonide.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluocinolone acetonide.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluocinolone acetonide.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluocinolone acetonide.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluocinolone acetonide.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluocinolone acetonide.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluocinolone acetonide.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Fluocinolone acetonide.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocinolone acetonide.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluocinolone acetonide.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinolone acetonide.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluocinolone acetonide.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluocinolone acetonide.
Linezolid The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Linezolid.
Clofarabine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Clofarabine.
Pemetrexed The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pemetrexed.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mycophenolate mofetil.
Dacarbazine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Penicillamine.
Azacitidine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Carboplatin.
Dactinomycin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dactinomycin.
Azathioprine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Estramustine.
Mitoxantrone The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mitoxantrone.
Lomustine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Nelarabine.
Stepronin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Brequinar.
Pirfenidone The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Obinutuzumab.
Vedolizumab The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Vedolizumab.

Target Protein

Glucocorticoid receptor NR3C1
Annexin A1 ANXA1
Annexin A2 ANXA2
Annexin A3 ANXA3
Annexin A4 ANXA4
Annexin A5 ANXA5
Phospholipase A2 PLA2G1B

Referensi & Sumber

Synthesis reference: Mills, J.S. and Bowers, A.; U.S. Patent 3,014,938; December 26, 1961; assigned to Syntex SA, Mexico.
Artikel (PubMed)
  • PMID: 17923537
    Goldstein DA, Godfrey DG, Hall A, Callanan DG, Jaffe GJ, Pearson PA, Usner DW, Comstock TL: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. 2007 Nov;125(11):1478-85. Epub 2007 Oct 8.
  • PMID: 17722513
    Brumm MV, Nguyen QD: Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Int J Nanomedicine. 2007;2(1):55-64.
  • PMID: 11006254
    Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P: Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75.
  • PMID: 1582642
    Knoch HG, Klug W, Hubner WD: Ointment treatment of 1st degree hemorrhoids. Comparison of the effectiveness of a phytogenic preparation with two new ointments containing synthetic drugs. Fortschr Med. 1992 Mar 20;110(8):135-8.
  • PMID: 25994877
    Sadiq MA, Agarwal A, Soliman MK, Hanout M, Sarwar S, Do DV, Nguyen QD: Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation. Expert Opin Drug Saf. 2015 Jul;14(7):1147-56. doi: 10.1517/14740338.2015.1041916. Epub 2015 May 20.
  • PMID: 19744340
    Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58.
  • PMID: 1874579
    Broggini M, Benvenuti C, Botta V, Broccali G: Pharmacokinetics of fluocinolone acetonide in patch versus cream formulations. Int J Clin Pharmacol Res. 1991;11(1):17-21.
Textbook
  • ISBN: 978-0-7817-6879-5
    Lemke T., Williams D., Roche V. and Zito W. (2008). Foye's Principles of Medicinal Chemistry (6th) (6th ed.). Lippincott Williams & Wilkins.
  • ISBN: 978-3-540-33861-1
    Becker M., Davis J. (2008). Surgical Management of Inflammatory Eye Disease. Springer.
  • Narayanan R. and Kuppermann B. (2010). Retinal pharmacotherapy. Elsevier.

Contoh Produk & Brand

Produk: 131 • International brands: 82
Produk
  • Capex
    Kit • 1 mg/1mg • Topical • US • Approved
  • Capex
    Shampoo • 0.01 % • Topical • Canada • Approved
  • Ciprofloxacin and Fluocinolone Acetonide
    Solution • - • Auricular (otic) • US • Approved
  • Ciprofloxacin and Fluocinolone Acetonide
    Solution • - • Auricular (otic) • US • Generic • Approved
  • Derma Smoothe/fs Liq 0.01%
    Emulsion • 0.01 % • Topical • Canada • Approved
  • Derma-Smoothe/FS
    Oil • 0.11 mg/1mL • Topical • US • Approved
  • Derma-Smoothe/FS
    Oil • 0.11 mg/1mL • Topical • US • Approved
  • Derma-Smoothe/FS
    Oil • 0.11 mg/1mL • Topical • US • Approved
Menampilkan 8 dari 131 produk.
International Brands
  • Biscosal — Onta Seiyaku
  • Boniderma — Boniscontro
  • Co-FIuosin — Sanchez-Covisa
  • Coderma — Biotrading
  • Cordes F — Ichthyol
  • Coriphate
  • Cortalar — Bergamon
  • Cortiderma — Gazzini
  • Cortiespec — Centrum
  • Cortiphate — Tokyo Tanabe

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul